JAMA Network Home
Sign In
Research Letter

Semaglutide and Tirzepatide Prescribing for Obesity in Patients With Preexisting Comorbid Cancers

JAMA Oncology 10.1001/jamaoncol.2025.4560

November 06, 2025 at 11:00 AM EST

Read the full article

This cohort study compares incident and prevalent prescription rates of glucagon-like peptide-1 receptor agonists among adults with at least 1 obesity-related comorbidity and newly diagnosed cancer.

Corresponding Author: Yuan Lu, ScD, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, 195 Church St, 5th Floor, New Haven, CT 06510 (y.lu@yale.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2025.4560?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=110625

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks